Can Dynamic Conformal Arc be an Option in Epidermoid Cervical Cancer Treatment?

Jacksson Sánchez, Nelly Muñoz, Luis Moreno Sánchez* and Frank Montero

Radiation oncologist, Dominican Republic

Abstract

Historically locally advanced cancer of the cervix has been treated with radiotherapy and brachytherapy and it was not until 1999 that the use of concurrent chemotherapy was formalized due to excellent results in terms of overall and disease-free survival. Box technique in radiotherapy is the most widely known providing excellent results, with some variations as oblique fields, but greatly increasing irradiation potentially healthy tissue, leading to the higher proportion of own side effects of each treatment. Therefore present a radiant treatment planning mode Dynamic Conformal Arc for cervical carcinoma. Treatment with dynamic conformal arc achieves better conformation of tumor and area to be treated, avoiding unnecessary doses to organs at risk (OAR), compared to conventional four fields irradiation technique (box technique), further significantly reduces the treatment time. Dynamic Conformal Arc (DAT) technique in the pelvis reduces irradiation dose in the organs at risk, making a good coverage of the clinical area to be treated, further decreasing the side effects. It could be considered as an alternative to conventional treatment of 4 fields or to the impossibility of intensity modulated radiation therapy (IMRT).

Keywords: Dynamic; Conformal; Arc; Cervix; Box; Technique, INCART, DAT

Introduction

Worldwide, cervical cancer is the fourth most common female malignancy in both incidence and mortality, resulting in approximately 527,600 new cases and 265,700 deaths annually [1,2]. Currently among the female population of Dominican Republic, cervical and breast cancer disputed the first and second place, statistics that resemble those seen in other developing countries in Latin America and the Caribbean. The high burden of cervical cancer in developing countries reflects the absence of cervical cancer prevention programs. The majority of the incident cases and deaths from cervical cancer, occur in developing countries, where resources for early detection and treatment are severely limited [3-5].

Cervical cancer and precancerous lesions behave as a sexually transmitted disease, especially associated with infection by the human papillomavirus (HPV), this being the causative agent of this disease in >99% of cases [6,7].

The definition of locally advanced cervical cancer, include patients with stage IB2 to IVA (Table 1). Surgery is not a therapeutic option for patients with stage IIIB, III and IV due to a high proportion of positive margins and high risk factors for recurrence. External beam radiation therapy with chemotherapy plus brachytherapy has been, so far, the treatment of choice for patients with locally advanced cervical cancer [8-11].

Methods and Materials

Patient

Female patient 68 years old with a history of hypertension, who was referred to the National Cancer Institute Rosa Emilia Sánchez de Tavares (INCART) Radiation Oncology Center (CRO) for radiation treatment concurrent with chemotherapy.

The patient referred genital bleeding and pain, so go to doctor who performs studies including biopsy, which concluded: squamous cell carcinoma moderately differentiated, infiltrating, therefore requested CT pelvis with contrast, in which large mass cervical was evidenced, with extension to the uterine myometrium, associated with dilated endometrial cavity (with approximate dimensions 66mm anteroposterior diameter) with sero-hematic contained therein, with slight irregularity of the serosa of the cervix, with subtle attenuation peripheral fat; turn left evidence obturator lymph nodes in region.

*Corresponding author: Radiation oncologist, Intra and Extracranial radiosurgery, brachytherapy, Coordinador de Radioncología, Instituto Nacional del Cáncer Rosa de Tavares (INCART), C/Correa y Cidrón, esq. Rafael Sánchez Ravelo. Zona Universitaria, Santo Domingo, Tel: (1127) 809-2892700; Email: radioncology@gmail.com
Table 1: FIGO Staging 2009.

| Stage | Description |
|-------|-------------|
| I     | The carcinoma is strictly confined to the cervix (extension to the uterine corpus should be disregarded). |
| IA    | Invasive cancer identified only microscopically. (All gross lesions with superficial invasion and Stage IB cancers.) Invasion is limited to measured stromal invasion with a maximum depth of 5 mm and no wider than 7 mm. |
| IA1   | Measured invasion of stroma ≤ 3 mm in depth and ≤ 7 mm width. |
| IA2   | Measured invasion of stroma N 3 mm and b 5 mm in depth and ≤ 7 mm width. |
| IB    | Clinical lesions confined to the cervix, or preclinical lesions greater than stage IA. |
| IR1   | Clinical lesions no greater than 4 cm in size. |
| IR2   | Clinical lesions N 4 cm in size. |
| II    | The carcinoma extends beyond the uterus, but has not extended onto the pelvic wall or to the lower third of vagina. |
| II A  | Involvement of up to the upper 2/3 of the vagina. No obvious parametrial involvement. |
| II A  | Clinically visible lesion ≤ 4 cm |
| II A  | Clinically visible lesion N 4 cm |
| II B  | Obvious parametrical involvement but not onto the pelvic sidewall. |
| III   | The carcinoma has extended onto the pelvic sidewall. On rectal examination, there is no cancer-free space between the tumor and pelvic sidewall. The tumor involves the lower third of the vagina. All cases of hydronephrosis or non-functioning kidney should be included unless they are known to be due to other causes. |
| III A | Involvement of the lower vagina but no extension onto pelvic sidewall. |
| III B | Extension onto the pelvic sidewall, or hydronephrosis/non-functioning kidney. |
| IV    | The carcinoma has extended beyond the true pelvis or has clinically involved the mucosa of the bladder and/or rectum. |
| IV A  | Spread to adjacent pelvic organs. |
| IV B  | Spread to distant organs. |

External beam radiation therapy was indicated and the treatment was performed in a Varian® Trilogy® linear accelerator, 120 multileaf colimator, making the target and OAR delimitation and planning in the Helios-Eclipse System® and treatment verification through portal vision and OBI image. The prescription dose was 180 cGy/daily to 4500 cGy, then BOOST to parametria 200 cGy/daily until 1000 cGy. The complete doses was 5500 cGy, with posterior 3D brachytherapy.

Tumor Description

i. US transvaginal: cervical canal with voluminous mass 5.6cm x 6.8cm x 4.6cm.

ii. Cystoscopy: Protrusion of the posterior rectal wall without bladder invasion

iii. Rectosigmoidscopy: a retroflexion output and anal canal, broad-based Polymorphic injury is evident.

Pelvis CT and definition of the target volume and OAR

The patient was treated in the supine position, with support leg positioning to ensure reproducibility. The cervix, uterus, regional lymph nodes, bladder, rectum and sigmoid were defined [12,13]. We make treatment planning based on a CTV45.0_1.8 + 5mm margin and PTV45.0_1.8 + 5mm margin. Subsequently it was defined a PTV10.0_2.0, which was limited to the parametrium.

Settlement field

It has been proposed a technique of dynamic arcs (DAT) for its acronym in English: dynamic arc treatment, whose purpose is based on the PTV using multileaf collimation at all times when they are performing the angular displacements of the gantry (Figure 1).

Therefore, to perform volume coverage planning have established two semi-arcs. The first arc with an angular displacement from 0° to 179° and the second arc of 179° to 359°. 100 control points were established for each 1.8° of displacement. Each checkpoint was assigned a weight of 0.0101.
(Figure 2), the formation of the PTV was made with multileaf (Figure 3).

**Patient Positioning**

The patient was checked every 3 days using portals fields each other orthogonal 10x10 cm² images and OBI. The structure of the pelvis was matched to the anatomy of the pelvis of digital radiography rebuilt.

**Discussion**

The Dynamic Conformal Arc plan compared with the conventional technique of box has two important advantages, including: dose and time (Figure 4).

**Dose**

As shown in Figure 5 the 60% isodose technique box for tissue level reaches subcutaneous and obviously undesired dose to the patient, while for the DAT technique does not show the 60% dose in said area. Isodose reaching the subcutaneous tissue with DAT is 35%. Having a differential decrease of approximately 25% over the conventional field.

Furthermore, the conformity of dose PTV DAT technical box is smaller. The compliance rate for PTV box was 1.09 while for the DAT was 1.07.

**Time**

The total time for the each conventional fields was 2.02 minutes while for DAT it was 1.4 min total treatment.

**Conclusion**

Technological progress in radiation therapy in the last 30 years has many treatments available to patients that offer high-precision radiotherapy, with consequent reduced toxicity, increased doses to achieve greater tumor control and reduced irradiation time.
The use of Dynamic Conformal Arc (ACD) for treatment of cervical cancer allows considerable reduction of tissue outside PTV while improved volume coverage planning and time machine.

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, et al. (2015) Global cancer statistics. 2012. CA Cancer J Clin 61(2): 87-108.
2. Bermudez A, Bhatla N, Leung E (2015) Cancer of the cervix uteri. Int J Gynaecol and Obstet 131 Suppl 2: S88-S95.
3. Denny L (2015) Control of Cancer of the Cervix in Low- and Middle-Income Countries. Ann Surg Oncol 22(3): 728-733.
4. GLOBOCAN (2012) Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012.
5. Moreno Sánchez L, Moreno Geraldo V, Reyes I, Marmolejos L, Reggio F (2013) Manejo del Cáncer Cérvico Uterino Localmente Avanzado: A Propósito de Un Caso. Rev Med Dom 74(1): 143-146.
6. Serman F (2002) Cáncer cervicouterino: epidemiología, historia natural y rol del virus papiloma humano. Perspectivas en prevención y tratamiento. Rev Chil Obst Ginecol 67(4): 318-323.
7. Tjong MY, Out TA, Ter Schegget J, Burger MPM, Van Der Vange N (2011) Epidemiologic and an mucosal immunologic aspects of HPV infection and HPVrelate cervical neoplasia in the lower female genital tract. Int J Gynecol Cancer 11(1): 9-17.
8. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, et al. (1999) Atkins. Concurrent Cisplatin-based Radiotherapy and Chemotherapy for locally advanced Cervical Cancer. N Engl J Med 340(15): 1144-1153.
9. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, et al. (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340(15): 1137-1143.
10. Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, et al. (2004) Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01. J Clin Oncol 22(5): 872-880.
11. Viswanathan AN, Beriwal S, De Los Santos JE, Demanes DJ, Gaffney D, et al. (2012) American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy. Brachytherapy 11(1): 47-52.
12. Lim K, Erickson B, Jurgenienk I, Gaffney D, Creutzberg CL, et al. (2015) Variability in clinical target volumen delineation for intensity modulated radiation therapy in 3 challenging cervix cancer scenarios. Pract Radiat Oncol 5(6): e557-e565.
13. Lee N, Riaz N, Lu J, Nadeem L, Jidae J (2015) Target Volume Delineation for Conformal and Intensity-Modulated Radiation Therapy. Springer 339-348.